Ensysce Biosciences Inc — Quarterly Cash Flow (NASDAQ:ENSC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 5.6 M4.61 M5.57 M3.18 M7.45 M Total liabilities 2.22 M1.89 M2.51 M2.3 M4.57 M Total equity 3.38 M2.72 M3.06 M874.71 K2.88 M Total liabilities & shareholders' equities 5.6 M4.61 M5.57 M3.18 M7.45 M Total debt ————— Net debt —————

News

Ensysce publishes phase 1 data on overdose-limiting opioid tech

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.05%

Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Ensysce Biosciences (NASDAQ:ENSC)

Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial

Ensysce Biosciences receives patent allowance in Brazil for pain tech

Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript

Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid

Ensysce Biosciences enrolls first patient in phase 3 pain drug trial

Ensysce Biosciences Narrows Loss in Q2

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

ensysce biosciences appoints baker tilly as new auditor